Graft vs Host Disease
Conditions
Brief summary
To determine if subjects with steroid refractory cGVHD can tolerate imatinib mesylate and whether their cGVHD responds to imatinib mesylate.
Interventions
DRUGImatinib
The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily.
Sponsors
Novartis
David Miklos
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Chronic graft-vs-host disease (cGVHD) requiring systemic therapy occurring \> 100 days after hematopoietic cell transplant with either: 1. Persistent steroid dependence defined as the inability to taper steroid treatment to less than 0.25 mg/kg/d prednisone or its equivalent for at least 3 months. 2. Progression of cGVHD signs and symptoms on steroid therapy equivalent to prednisone 0.5 mg/kg/d for at least 1 month. * At least one of the following manifestations: 1. Skin changes (rash, sclerosis, fasciitis, or ulceration). 2. Abnormal eye wetness ≤ 5 mm as measured by Schirmer's test. 3. Oral mucosal changes (erythema, lichenoid changes, ulcers, or mucoceles). 4. Thrombocytopenia (platelets \< 50,000/uL). 5. Abnormal liver function testing defined as alkaline phosphatase, AST, ALT, or total bilirubin \> upper limit of normal (ULN). 6. Bronchiolitis obliterans (diagnosed by a \> 5% annual decline in FEV1 with the lowest post-transplant FEV1/FVC \< 0.8 and an appropriate CT scan or lung biopsy). * Has been on a fixed dose of steroids or a fixed dose of steroids and one other immunosuppressant (cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or extracorporeal photopheresis) for ≥ 30 days before starting imatinib. * Life expectancy ≥ 6 months. * Ability to understand and willingness to sign a written informed consent document. * Karnofsky performance status ≥ 3 50% (Appendix B). * At least 18 years of age. * If a female of reproductive potential (defined as having at least 1 menstrual period in the past 12 months), must have a negative pregnancy test performed ≤ 7 days before starting study drug. * If a female of reproductive potential, agrees to use contraception for the duration of the trial. * Total bilirubin \< 1.5X ULN. * Aspartate transaminase (AST) \< 2.5 x ULN. * Alanine aminotransferase (ALT) \< 2.5 x ULN. * Alkaline phosphatase \< 2.5 x ULN. * Absolute neutrophil count (ANC) \> 500/uL (growth factor supplementation is allowed). * Hematocrit \> 26% (transfusion support is allowed). * Platelet count \> 20,000/uL.
Exclusion criteria
* Received another investigational agent ≤ 30 days before starting the study drug. * Ongoing intercurrent illness such as an infection not responsive to antibiotics, antiviral medicines, or antifungal medicines. * Progressive malignant disease. * Secondary malignancy that has not been effectively treated within the past 5 years (except localized basal cell or squamous cell carcinoma). * Imatinib intolerance or allergy. * Participant is breast-feeding. * Not willing to comply with treatment or response evaluation. * Received an allogeneic cell product \[including donor lymphocyte infusion (DLI) or hematopoietic cell boost\] ≤ 100 days before starting study drug. * Steroid and/or immunosuppressant dose has changed ≤ 30 days before starting study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The frequency of adverse events graded according to the CTCAE will be the primary endpoint | Subjects will be monitored at 1, 4, 8, 16, and 24 weeks. |
Countries
United States
Outcome results
None listed